{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:21Z","timestamp":1786982781653,"version":"build-2736575974"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40265-026-02329-7","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:42:03Z","timestamp":1779190923000},"page":"1075-1090","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["EGFR Exon 20 Insertion\u2013Mutated Non-Small Cell Lung Cancer: Current Treatment Landscape and Future Directions"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4517-1113","authenticated-orcid":false,"given":"Eunice L. Y.","family":"Lau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor Rashidha Binte Meera","family":"Sahib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina Ysha P.","family":"Cangco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7292-1114","authenticated-orcid":false,"given":"Aaron C.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"issue":"3","key":"2329_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"18_suppl","key":"2329_CR2","doi-asserted-by":"publisher","first-page":"7082","DOI":"10.1200\/jco.2006.24.18_suppl.7082","volume":"24","author":"S Navada","year":"2006","unstructured":"Navada S, Lai P, Schwartz AG, Kalemkerian GP. Temporal trends in small cell lung cancer: Analysis of the national Surveillance, Epidemiology, and End-Results (SEER) database. J Clin Oncol. 2006;24(18_suppl):7082\u20137082. https:\/\/doi.org\/10.1200\/jco.2006.24.18_suppl.7082.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2329_CR3","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/jco.21.01626","volume":"40","author":"AC Tan","year":"2022","unstructured":"Tan AC, Tan DSW. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol. 2022;40(6):611\u201325. https:\/\/doi.org\/10.1200\/jco.21.01626.","journal-title":"J Clin Oncol"},{"issue":"24","key":"2329_CR4","doi-asserted-by":"publisher","first-page":"8919","DOI":"10.1158\/0008-5472.Can-04-2818","volume":"64","author":"T Kosaka","year":"2004","unstructured":"Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004;64(24):8919\u201323. https:\/\/doi.org\/10.1158\/0008-5472.Can-04-2818.","journal-title":"Cancer Res"},{"issue":"15","key":"2329_CR5","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1200\/jco.2007.14.8494","volume":"26","author":"LV Sequist","year":"2008","unstructured":"Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, J\u00e4nne PA, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008;26(15):2442\u20139. https:\/\/doi.org\/10.1200\/jco.2007.14.8494.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2329_CR6","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947\u201357. https:\/\/doi.org\/10.1056\/NEJMoa0810699.","journal-title":"N Engl J Med"},{"issue":"8","key":"2329_CR7","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/s1470-2045(11)70184-x","volume":"12","author":"C Zhou","year":"2011","unstructured":"Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735\u201342. https:\/\/doi.org\/10.1016\/s1470-2045(11)70184-x.","journal-title":"Lancet Oncol"},{"issue":"5","key":"2329_CR8","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/s1470-2045(16)30033-x","volume":"17","author":"K Park","year":"2016","unstructured":"Park K, Tan EH, O\u2019Byrne K, Zhang L, Boyer M, Mok T, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17(5):577\u201389. https:\/\/doi.org\/10.1016\/s1470-2045(16)30033-x.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2329_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"J-C Soria","year":"2018","unstructured":"Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee Ki H, et al. Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer. N Engl J Med. 2018;378(2):113\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1713137.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"2329_CR10","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1038\/onc.2009.198","volume":"28","author":"AF Gazdar","year":"2009","unstructured":"Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28(Suppl 1):S24-31. https:\/\/doi.org\/10.1038\/onc.2009.198.","journal-title":"Oncogene"},{"issue":"3","key":"2329_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247620","volume":"16","author":"H Burnett","year":"2021","unstructured":"Burnett H, Emich H, Carroll C, Stapleton N, Mahadevia P, Li T. Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. PLoS ONE. 2021;16(3):e0247620. https:\/\/doi.org\/10.1371\/journal.pone.0247620.","journal-title":"PLoS ONE"},{"issue":"2","key":"2329_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/JTO.0b013e3182779d18","volume":"8","author":"GR Oxnard","year":"2013","unstructured":"Oxnard GR, Lo PC, Nishino M, Dahlberg SE, Lindeman NI, Butaney M, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013;8(2):179\u201384. https:\/\/doi.org\/10.1097\/JTO.0b013e3182779d18.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"2329_CR13","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1158\/2159-8290.Cd-16-1337","volume":"7","author":"EJ Jordan","year":"2017","unstructured":"Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. 2017;7(6):596\u2013609. https:\/\/doi.org\/10.1158\/2159-8290.Cd-16-1337.","journal-title":"Cancer Discov"},{"issue":"2","key":"2329_CR14","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1158\/1535-7163.Mct-12-0620","volume":"12","author":"ME Arcila","year":"2013","unstructured":"Arcila ME, Nafa K, Chaft JE, Rekhtman N, Lau C, Reva BA, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013;12(2):220\u20139. https:\/\/doi.org\/10.1158\/1535-7163.Mct-12-0620.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2329_CR15","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/s1470-2045(11)70129-2","volume":"13","author":"H Yasuda","year":"2012","unstructured":"Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol. 2012;13(1):e23-31. https:\/\/doi.org\/10.1016\/s1470-2045(11)70129-2.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2329_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40880-017-0187-6","volume":"36","author":"J Cho","year":"2017","unstructured":"Cho J, Choi SM, Lee J, Lee CH, Lee SM, Kim DW, et al. Proportion and clinical features of never-smokers with non-small cell lung cancer. Chin J Cancer. 2017;36(1):20. https:\/\/doi.org\/10.1186\/s40880-017-0187-6.","journal-title":"Chin J Cancer"},{"issue":"5","key":"2329_CR17","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/cncr.23679","volume":"113","author":"T Yano","year":"2008","unstructured":"Yano T, Miura N, Takenaka T, Haro A, Okazaki H, Ohba T, et al. Never-smoking nonsmall cell lung cancer as a separate entity: clinicopathologic features and survival. Cancer. 2008;113(5):1012\u20138. https:\/\/doi.org\/10.1002\/cncr.23679.","journal-title":"Cancer"},{"issue":"1","key":"2329_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-019-0038-9","volume":"4","author":"S Vyse","year":"2019","unstructured":"Vyse S, Huang PH. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduct Target Ther. 2019;4(1):5. https:\/\/doi.org\/10.1038\/s41392-019-0038-9.","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"2329_CR19","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1111\/cas.12996","volume":"107","author":"Y Kobayashi","year":"2016","unstructured":"Kobayashi Y, Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy. Cancer Sci. 2016;107(9):1179\u201386. https:\/\/doi.org\/10.1111\/cas.12996.","journal-title":"Cancer Sci"},{"issue":"6","key":"2329_CR20","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.jtho.2023.01.086","volume":"18","author":"SI Ou","year":"2023","unstructured":"Ou SI, Hong JL, Christopoulos P, Lin HM, Vincent S, Churchill EN, et al. Distribution and detectability of EGFR exon 20 insertion variants in NSCLC. J Thorac Oncol. 2023;18(6):744\u201354. https:\/\/doi.org\/10.1016\/j.jtho.2023.01.086.","journal-title":"J Thorac Oncol"},{"key":"2329_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102671","volume":"124","author":"M Dorta-Su\u00e1rez","year":"2024","unstructured":"Dorta-Su\u00e1rez M, de Miguel M, Amor-Carro O, Calder\u00f3n JM, Gonz\u00e1lez-Ortega M, Rodr\u00edguez-Abreu D. The state of the art of EGFR exon 20 insertions in non-small cell lung cancer: diagnosis and future perspectives. Cancer Treat Rev. 2024;124:102671. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102671.","journal-title":"Cancer Treat Rev"},{"issue":"7878","key":"2329_CR22","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","volume":"597","author":"JP Robichaux","year":"2021","unstructured":"Robichaux JP, Le X, Vijayan RSK, Hicks JK, Heeke S, Elamin YY, et al. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature. 2021;597(7878):732\u20137. https:\/\/doi.org\/10.1038\/s41586-021-03898-1.","journal-title":"Nature"},{"issue":"18","key":"2329_CR23","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1002\/cncr.29493","volume":"121","author":"J Naidoo","year":"2015","unstructured":"Naidoo J, Sima CS, Rodriguez K, Busby N, Nafa K, Ladanyi M, et al. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: clinical outcomes and response to erlotinib. Cancer. 2015;121(18):3212\u201320. https:\/\/doi.org\/10.1002\/cncr.29493.","journal-title":"Cancer"},{"key":"2329_CR24","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.lungcan.2020.03.014","volume":"145","author":"G Yang","year":"2020","unstructured":"Yang G, Li J, Xu H, Yang Y, Yang L, Xu F, et al. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: molecular heterogeneity and treatment outcome from nationwide real-world study. Lung Cancer. 2020;145:186\u201394. https:\/\/doi.org\/10.1016\/j.lungcan.2020.03.014.","journal-title":"Lung Cancer"},{"issue":"6","key":"2329_CR25","doi-asserted-by":"publisher","first-page":"e859","DOI":"10.1016\/j.cllc.2021.04.009","volume":"22","author":"JL Leal","year":"2021","unstructured":"Leal JL, Alexander M, Itchins M, Wright GM, Kao S, Hughes BGM, et al. EGFR exon 20 insertion mutations: clinicopathological characteristics and treatment outcomes in advanced non-small cell lung cancer. Clin Lung Cancer. 2021;22(6):e859\u201369. https:\/\/doi.org\/10.1016\/j.cllc.2021.04.009.","journal-title":"Clin Lung Cancer"},{"issue":"7","key":"2329_CR26","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.cllc.2022.07.007","volume":"23","author":"N Girard","year":"2022","unstructured":"Girard N, Minchom A, Ou S-HI, Gadgeel SM, Trigo J, Viteri S, et al. Comparative clinical outcomes between EGFR Ex20ins and wildtype NSCLC treated with immune checkpoint inhibitors. Clin Lung Cancer. 2022;23(7):571\u20137. https:\/\/doi.org\/10.1016\/j.cllc.2022.07.007.","journal-title":"Clin Lung Cancer"},{"issue":"30","key":"2329_CR27","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1200\/jco.21.00662","volume":"39","author":"K Park","year":"2021","unstructured":"Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS Phase I Study. J Clin Oncol. 2021;39(30):3391\u2013402. https:\/\/doi.org\/10.1200\/jco.21.00662.","journal-title":"J Clin Oncol"},{"issue":"22","key":"2329_CR28","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","volume":"389","author":"C Zhou","year":"2023","unstructured":"Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, et al. Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions. N Engl J Med. 2023;389(22):2039\u201351. https:\/\/doi.org\/10.1056\/NEJMoa2306441.","journal-title":"N Engl J Med"},{"issue":"29","key":"2329_CR29","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1200\/jco-25-00788","volume":"43","author":"JC-H Yang","year":"2025","unstructured":"Yang JC-H, Wang M, Doucet L, Fan Y, Lv D, Sun M, et al. Phase II dose-randomized study of Sunvozertinib in platinum-pretreated non-small cell lung cancer with Epidermal Growth Factor Receptor exon 20 insertion mutations (WU-KONG1B). J Clin Oncol. 2025;43(29):3198\u2013208. https:\/\/doi.org\/10.1200\/jco-25-00788.","journal-title":"J Clin Oncol"},{"key":"2329_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115590","volume":"258","author":"B Liu","year":"2023","unstructured":"Liu B, Gao F, Zhao H, Yuan S, Peng X, Zhang P, et al. Discovery of YK-029A, a novel mutant EGFR inhibitor targeting both T790 M and exon 20 insertion mutations, as a treatment for NSCLC. Eur J Med Chem. 2023;258:115590. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115590.","journal-title":"Eur J Med Chem"},{"issue":"2","key":"2329_CR31","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.cllc.2023.11.010","volume":"25","author":"J Liu","year":"2024","unstructured":"Liu J, Xiang Y, Fang T, Zeng L, Sun A, Lin Y, et al. Advances in the diagnosis and treatment of advanced non\u2013small-cell lung cancer with EGFR exon 20 insertion mutation. Clin Lung Cancer. 2024;25(2):100\u20138. https:\/\/doi.org\/10.1016\/j.cllc.2023.11.010.","journal-title":"Clin Lung Cancer"},{"issue":"4","key":"2329_CR32","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.62347\/wtmu5537","volume":"15","author":"C Yuan","year":"2025","unstructured":"Yuan C, Yu JY, Zeng CX, Wang MC, Zhang S, Huang YB, et al. New advances in the treatment of EGFR exon20ins mutant advanced NSCLC. Am J Cancer Res. 2025;15(4):1852\u201373. https:\/\/doi.org\/10.62347\/wtmu5537.","journal-title":"Am J Cancer Res"},{"issue":"9","key":"2329_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100803","volume":"6","author":"BV Miyamura","year":"2025","unstructured":"Miyamura BV, Mambetsariev I, Fricke J, Arias-Romero J, Cadman K, Shrestha S, et al. Current paradigm of EGFR(ins20) in non-small cell lung cancer: A long way forward. Med. 2025;6(9):100803. https:\/\/doi.org\/10.1016\/j.medj.2025.100803.","journal-title":"Med"},{"issue":"216","key":"2329_CR34","doi-asserted-by":"publisher","first-page":"216ra177","DOI":"10.1126\/scitranslmed.3007205","volume":"5","author":"H Yasuda","year":"2013","unstructured":"Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 2013;5(216):216ra177. https:\/\/doi.org\/10.1126\/scitranslmed.3007205.","journal-title":"Sci Transl Med"},{"issue":"7","key":"2329_CR35","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1158\/2159-8290.Cd-20-1683","volume":"11","author":"F Gonzalvez","year":"2021","unstructured":"Gonzalvez F, Vincent S, Baker TE, Gould AE, Li S, Wardwell SD, et al. Mobocertinib (TAK-788): a targeted inhibitor of EGFR exon 20 insertion mutants in non-small cell lung cancer. Cancer Discov. 2021;11(7):1672\u201387. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-1683.","journal-title":"Cancer Discov"},{"issue":"3","key":"2329_CR36","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.bbapap.2009.12.010","volume":"1804","author":"MJ Eck","year":"2010","unstructured":"Eck MJ, Yun CH. Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer. Biochim Biophys Acta. 2010;1804(3):559\u201366. https:\/\/doi.org\/10.1016\/j.bbapap.2009.12.010.","journal-title":"Biochim Biophys Acta"},{"issue":"17","key":"2329_CR37","doi-asserted-by":"publisher","first-page":"11656","DOI":"10.1021\/acs.jmedchem.3c00875","volume":"66","author":"H Chen","year":"2023","unstructured":"Chen H, Hu S, Patterson AV, Smaill JB, Ding K, Lu X. Structural mechanism and inhibitors targeting EGFR exon 20 insertion (Ex20ins) mutations. J Med Chem. 2023;66(17):11656\u201371. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c00875.","journal-title":"J Med Chem"},{"key":"2329_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2020.100051","author":"P Vasconcelos","year":"2020","unstructured":"Vasconcelos P, Gergis C, Viray H, Varkaris A, Fujii M, Rangachari D, et al. EGFR-A763_Y764insFQEA is a unique exon 20 insertion mutation that displays sensitivity to approved and in-development lung cancer EGFR tyrosine kinase inhibitors. JTO Clin Res Rep. 2020. https:\/\/doi.org\/10.1016\/j.jtocrr.2020.100051.","journal-title":"JTO Clin Res Rep"},{"issue":"6","key":"2329_CR39","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1200\/jco.2007.12.9858","volume":"26","author":"DA Eberhard","year":"2008","unstructured":"Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol. 2008;26(6):983\u201394. https:\/\/doi.org\/10.1200\/jco.2007.12.9858.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2329_CR40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/jclinpath-2012-201194","volume":"66","author":"G Ellison","year":"2013","unstructured":"Ellison G, Zhu G, Moulis A, Dearden S, Speake G, McCormack R. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol. 2013;66(2):79\u201389. https:\/\/doi.org\/10.1136\/jclinpath-2012-201194.","journal-title":"J Clin Pathol"},{"issue":"1","key":"2329_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-17394-7","volume":"12","author":"CI Shen","year":"2022","unstructured":"Shen CI, Chiang CL, Shiao TH, Luo YH, Chao HS, Huang HC, et al. Real-world evidence of the intrinsic limitations of PCR-based EGFR mutation assay in non-small cell lung cancer. Sci Rep. 2022;12(1):13566. https:\/\/doi.org\/10.1038\/s41598-022-17394-7.","journal-title":"Sci Rep"},{"issue":"3","key":"2329_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100285","volume":"3","author":"HM Lin","year":"2022","unstructured":"Lin HM, Yin Y, Crossland V, Wu Y, Ou SI. EGFR testing patterns and detection of EGFR exon 20 insertions in the United States. JTO Clin Res Rep. 2022;3(3):100285. https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100285.","journal-title":"JTO Clin Res Rep"},{"issue":"5","key":"2329_CR43","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/gcc.22047","volume":"52","author":"K Tuononen","year":"2013","unstructured":"Tuononen K, M\u00e4ki-Nevala S, Sarhadi VK, Wirtanen A, R\u00f6nty M, Salmenkivi K, et al. Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS. Genes Chromosomes Cancer. 2013;52(5):503\u201311. https:\/\/doi.org\/10.1002\/gcc.22047.","journal-title":"Genes Chromosomes Cancer"},{"issue":"2","key":"2329_CR44","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/1878-0261.13327","volume":"17","author":"S Viteri","year":"2023","unstructured":"Viteri S, Minchom A, Bazhenova L, Ou SI, Bauml JM, Shell SA, et al. Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real-world genomic datasets. Mol Oncol. 2023;17(2):230\u20137. https:\/\/doi.org\/10.1002\/1878-0261.13327.","journal-title":"Mol Oncol"},{"issue":"1","key":"2329_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-63821-2","volume":"14","author":"MA Ihle","year":"2024","unstructured":"Ihle MA, Heydt C, Schultheis AM, St\u00f6hr R, Haller F, Herold S, et al. Multinational proficiency tests for EGFR exon 20 insertions reveal that the assay design matters. Sci Rep. 2024;14(1):13069. https:\/\/doi.org\/10.1038\/s41598-024-63821-2.","journal-title":"Sci Rep"},{"issue":"10","key":"2329_CR46","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.jtho.2018.06.019","volume":"13","author":"JW Riess","year":"2018","unstructured":"Riess JW, Gandara DR, Frampton GM, Madison R, Peled N, Bufill JA, et al. Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC. J Thorac Oncol. 2018;13(10):1560\u20138. https:\/\/doi.org\/10.1016\/j.jtho.2018.06.019.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2329_CR47","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jtho.2023.08.029","volume":"19","author":"A Hamada","year":"2024","unstructured":"Hamada A, Suda K, Nishino M, Obata K, Oiki H, Fukami T, et al. Secondary mutations of the EGFR gene that confer resistance to Mobocertinib in EGFR exon 20 insertion. J Thorac Oncol. 2024;19(1):71\u20139. https:\/\/doi.org\/10.1016\/j.jtho.2023.08.029.","journal-title":"J Thorac Oncol"},{"issue":"Suppl 3","key":"2329_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12919-023-00287-6","volume":"18","author":"MJ Hochmair","year":"2024","unstructured":"Hochmair MJ, Unk M, Spasic J, Ceri\u0107 T, Konsoulova A, Dediu M, et al. Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability. BMC Proc. 2024;18(Suppl 3):2. https:\/\/doi.org\/10.1186\/s12919-023-00287-6.","journal-title":"BMC Proc"},{"issue":"7","key":"2329_CR49","doi-asserted-by":"publisher","first-page":"649","DOI":"10.18553\/jmcp.2024.30.7.649","volume":"30","author":"IM Abbass","year":"2024","unstructured":"Abbass IM, Sheinson DM, Shah A, Gondos A, Ogale S. Cost-effectiveness of large-panel next-generation sequencing in guiding first-line treatment decisions for patients with nonsquamous advanced non-small cell lung cancer. J Manag Care Spec Pharm. 2024;30(7):649\u201359. https:\/\/doi.org\/10.18553\/jmcp.2024.30.7.649.","journal-title":"J Manag Care Spec Pharm"},{"key":"2329_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1399975","volume":"15","author":"M Hu","year":"2024","unstructured":"Hu M, Zhong C, Wang J, Chen J, Zhou T. Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations. Front Immunol. 2024;15:1399975. https:\/\/doi.org\/10.3389\/fimmu.2024.1399975.","journal-title":"Front Immunol"},{"key":"2329_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032505","author":"GMS Casagrande","year":"2023","unstructured":"Casagrande GMS, Silva MO, Reis RM, Leal LF. Liquid biopsy for lung cancer: Up-to-date and perspectives for screening programs. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24032505.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2329_CR52","doi-asserted-by":"publisher","first-page":"488","DOI":"10.18632\/oncotarget.22470","volume":"9","author":"M Provencio","year":"2018","unstructured":"Provencio M, Torrente M, Calvo V, P\u00e9rez-Callejo D, Guti\u00e9rrez L, Franco F, et al. Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients. Oncotarget. 2018;9(1):488\u201394. https:\/\/doi.org\/10.18632\/oncotarget.22470.","journal-title":"Oncotarget"},{"issue":"15","key":"2329_CR53","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1158\/1078-0432.Ccr-19-0624","volume":"25","author":"NB Leighl","year":"2019","unstructured":"Leighl NB, Page RD, Raymond VM, Daniel DB, Divers SG, Reckamp KL, et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. Clin Cancer Res. 2019;25(15):4691\u2013700. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-0624.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2329_CR54","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","volume":"16","author":"C Rolfo","year":"2021","unstructured":"Rolfo C, Mack P, Scagliotti GV, Aggarwal C, Arcila ME, Barlesi F, et al. Liquid biopsy for advanced NSCLC: A consensus statement from the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021;16(10):1647\u201362. https:\/\/doi.org\/10.1016\/j.jtho.2021.06.017.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"2329_CR55","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1159\/000492710","volume":"63","author":"P Pisapia","year":"2019","unstructured":"Pisapia P, Malapelle U, Troncone G. Liquid biopsy and lung cancer. Acta Cytol. 2019;63(6):489\u201396. https:\/\/doi.org\/10.1159\/000492710.","journal-title":"Acta Cytol"},{"key":"2329_CR56","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf390","author":"KT Chen","year":"2025","unstructured":"Chen KT, Sethunath V, Ebot E, Decker B, Gasco A, Ross JS, et al. Coverage of actionable alterations in non-small cell lung cancer by hybrid capture-based FoundationOne\u00aeCDx compared with amplicon-based OncomineDX. Oncologist. 2025. https:\/\/doi.org\/10.1093\/oncolo\/oyaf390.","journal-title":"Oncologist"},{"issue":"12","key":"2329_CR57","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1038\/nprot.2016.150","volume":"11","author":"H Fang","year":"2016","unstructured":"Fang H, Bergmann EA, Arora K, Vacic V, Zody MC, Iossifov I, et al. Indel variant analysis of short-read sequencing data with Scalpel. Nat Protoc. 2016;11(12):2529\u201348. https:\/\/doi.org\/10.1038\/nprot.2016.150.","journal-title":"Nat Protoc"},{"issue":"15","key":"2329_CR58","doi-asserted-by":"publisher","first-page":"4877","DOI":"10.1158\/1078-0432.Ccr-07-5123","volume":"14","author":"JY Wu","year":"2008","unstructured":"Wu JY, Wu SG, Yang CH, Gow CH, Chang YL, Yu CJ, et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res. 2008;14(15):4877\u201382. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-07-5123.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2329_CR59","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/s1470-2045(15)00026-1","volume":"16","author":"JC Yang","year":"2015","unstructured":"Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16(7):830\u20138. https:\/\/doi.org\/10.1016\/s1470-2045(15)00026-1.","journal-title":"Lancet Oncol"},{"key":"2329_CR60","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.lungcan.2021.10.006","volume":"162","author":"H Yasuda","year":"2021","unstructured":"Yasuda H, Ichihara E, Sakakibara-Konishi J, Zenke Y, Takeuchi S, Morise M, et al. A phase I\/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer. Lung Cancer. 2021;162:140\u20136. https:\/\/doi.org\/10.1016\/j.lungcan.2021.10.006.","journal-title":"Lung Cancer"},{"key":"2329_CR61","unstructured":"FDA, U. FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer. 2021 05\/21\/2021 [cited 2026 20 January 2026]; Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-amivantamab-vmjw-metastatic-non-small-cell-lung-cancer."},{"issue":"3","key":"2329_CR62","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jtho.2023.11.020","volume":"19","author":"K Wang","year":"2024","unstructured":"Wang K, Du R, Myall NJ, Lewis WE, Uy N, Hong L, et al. Real-world efficacy and safety of amivantamab for EGFR-mutant NSCLC. J Thorac Oncol. 2024;19(3):500\u20136. https:\/\/doi.org\/10.1016\/j.jtho.2023.11.020.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"2329_CR63","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s11523-025-01182-0","volume":"20","author":"RE Sanborn","year":"2025","unstructured":"Sanborn RE, Zhou C, Tang KJ, Cho BC, Cheng S, Popat S, et al. Amivantamab-chemotherapy in non-small cell lung cancer with EGFR exon 20 insertions: impact of treatment crossover and other endpoints from the phase III PAPILLON study. Target Oncol. 2025;20(6):979\u201389. https:\/\/doi.org\/10.1007\/s11523-025-01182-0.","journal-title":"Target Oncol"},{"key":"2329_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2026.109302","volume":"213","author":"C Zhou","year":"2026","unstructured":"Zhou C, Tang KJ, Liu B, Kim SW, Kitazono S, Ono A, et al. Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis. Lung Cancer. 2026;213:109302. https:\/\/doi.org\/10.1016\/j.lungcan.2026.109302.","journal-title":"Lung Cancer"},{"key":"2329_CR65","unstructured":"Administration, U.S.F.D. FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications. 2024 [cited 2026; Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-amivantamab-vmjw-egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer-indications."},{"key":"2329_CR66","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf194","author":"N Florez","year":"2025","unstructured":"Florez N, LeBoeuf NR, Rotow J, Marks JA, Sabari JK, Arrieta O, et al. Mitigation and management of adverse events associated with amivantamab therapy. Oncologist. 2025. https:\/\/doi.org\/10.1093\/oncolo\/oyaf194.","journal-title":"Oncologist"},{"issue":"10","key":"2329_CR67","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.jtho.2025.07.117","volume":"20","author":"BC Cho","year":"2025","unstructured":"Cho BC, Li W, Spira AI, Sauder M, Feldman J, Bozorgmehr F, et al. Enhanced versus standard dermatologic management with amivantamab-lazertinib in EGFR-mutated advanced NSCLC: The COCOON global randomized controlled trial. J Thorac Oncol. 2025;20(10):1517\u201330. https:\/\/doi.org\/10.1016\/j.jtho.2025.07.117.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"2329_CR68","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jtho.2025.01.018","volume":"20","author":"AI Spira","year":"2025","unstructured":"Spira AI, Paz-Ares L, Han JY, Shih JY, Mascaux C, Roy UB, et al. Preventing infusion-related reactions with intravenous amivantamab-results from SKIPPirr, a phase 2 study: A brief report. J Thorac Oncol. 2025;20(6):809\u201316. https:\/\/doi.org\/10.1016\/j.jtho.2025.01.018.","journal-title":"J Thorac Oncol"},{"issue":"30","key":"2329_CR69","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1200\/jco.24.01001","volume":"42","author":"NB Leighl","year":"2024","unstructured":"Leighl NB, Akamatsu H, Lim SM, Cheng Y, Minchom AR, Marmarelis ME, et al. Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory epidermal growth factor receptor-mutated non-small cell lung cancer: primary results from the phase III PALOMA-3 study. J Clin Oncol. 2024;42(30):3593\u2013605. https:\/\/doi.org\/10.1200\/jco.24.01001.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2329_CR70","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.4761","volume":"7","author":"C Zhou","year":"2021","unstructured":"Zhou C, Ramalingam SS, Kim TM, Kim SW, Yang JC, Riely GJ, et al. Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: A phase 1\/2 open-label nonrandomized clinical trial. JAMA Oncol. 2021;7(12):e214761. https:\/\/doi.org\/10.1001\/jamaoncol.2021.4761.","journal-title":"JAMA Oncol"},{"issue":"13","key":"2329_CR71","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1200\/jco-24-01269","volume":"43","author":"PA J\u00e4nne","year":"2025","unstructured":"J\u00e4nne PA, Wang BC, Cho BC, Zhao J, Li J, Hochmair M, et al. First-line mobocertinib versus platinum-based chemotherapy in patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer in the phase III EXCLAIM-2 trial. J Clin Oncol. 2025;43(13):1553\u201363. https:\/\/doi.org\/10.1200\/jco-24-01269.","journal-title":"J Clin Oncol"},{"issue":"26","key":"2329_CR72","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1200\/jco.23.00152","volume":"41","author":"Z Piotrowska","year":"2023","unstructured":"Piotrowska Z, Tan DS, Smit EF, Spira AI, Soo RA, Nguyen D, et al. Safety, tolerability, and antitumor activity of Zipalertinib among patients with non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions. J Clin Oncol. 2023;41(26):4218\u201325. https:\/\/doi.org\/10.1200\/jco.23.00152.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2329_CR73","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.jtho.2023.09.033","volume":"18","author":"B Han","year":"2023","unstructured":"Han B, Zhou C, Zheng W, Wu L, Ma Z, Wang H, et al. OA03.04 a Phase 1b study of furmonertinib, an oral, brain penetrant, selective EGFR inhibitor, in patients with advanced NSCLC with EGFR exon 20 insertions. J Thorac Oncol. 2023;18(11):S49. https:\/\/doi.org\/10.1016\/j.jtho.2023.09.033.","journal-title":"J Thorac Oncol"},{"issue":"16_suppl","key":"2329_CR74","doi-asserted-by":"publisher","first-page":"TPS8671","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS8671","volume":"42","author":"HA Yu","year":"2024","unstructured":"Yu HA, Besse B, Nishio M, Cheng Y, Wei L, Wacheck V, et al. REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations. J Clin Oncol. 2024;42(16_suppl):TPS8671\u2013TPS8671. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.TPS8671.","journal-title":"J Clin Oncol"},{"key":"2329_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.108066","volume":"199","author":"A Spira","year":"2025","unstructured":"Spira A, Cho BC, Felip E, Garon EB, Goto K, Johnson M, et al. FURVENT: phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004). Lung Cancer. 2025;199:108066. https:\/\/doi.org\/10.1016\/j.lungcan.2024.108066.","journal-title":"Lung Cancer"},{"issue":"5","key":"2329_CR76","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.medj.2024.02.011","volume":"5","author":"L Zeng","year":"2024","unstructured":"Zeng L, Song L, Liu L, Wu F, Xu Q, Yan H, et al. First-in-human phase I study of BEBT-109 in previously treated EGFR exon 20 insertion-mutated advanced non-small cell lung cancer. Med. 2024;5(5):445-458.e3. https:\/\/doi.org\/10.1016\/j.medj.2024.02.011.","journal-title":"Med"},{"issue":"3","key":"2329_CR77","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1158\/0008-5472.Can-25-3502","volume":"86","author":"MR Junttila","year":"2026","unstructured":"Junttila MR, Repellin CE, Salaniwal S, Warne R, Lee Y, Kim H, et al. Enozertinib is a selective, brain-penetrant EGFR inhibitor for treating non-small cell lung cancers with EGFR exon 20 and atypical mutations. Cancer Res. 2026;86(3):759\u201372. https:\/\/doi.org\/10.1158\/0008-5472.Can-25-3502.","journal-title":"Cancer Res"},{"key":"2329_CR78","doi-asserted-by":"publisher","first-page":"S1039","DOI":"10.1016\/j.annonc.2025.08.2577","volume":"36","author":"JJ Yang","year":"2025","unstructured":"Yang JJ, Wu YL, Zhao Y, Wang ZH, Duan J, Zhang Y, et al. 1953P PLB-1004 in advanced non-small cell lung cancer (NSCLC) with exon 20 insertion mutations (ex20ins): a multicenter, single-arm, phase II study. Ann Oncol. 2025;36:S1039. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.2577.","journal-title":"Ann Oncol"},{"issue":"8_Supplement_1","key":"2329_CR79","doi-asserted-by":"publisher","first-page":"5604","DOI":"10.1158\/1538-7445.Am2025-5604","volume":"85","author":"MR Yu","year":"2025","unstructured":"Yu MR, Lee JB, Lee KH, Hong MH, Lim SM, Cho BC. Abstract 5604: antitumor activity of YH42946, a potent tyrosine kinase inhibitor, in NSCLC harboring EGFR exon 20 insertion mutations. Cancer Res. 2025;85(8_Supplement_1):5604\u20135604. https:\/\/doi.org\/10.1158\/1538-7445.Am2025-5604.","journal-title":"Cancer Res"},{"issue":"2","key":"2329_CR80","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jtho.2023.09.1449","volume":"19","author":"J Duan","year":"2024","unstructured":"Duan J, Wu L, Yang K, Zhao J, Zhao Y, Dai X, et al. Safety, tolerability, pharmacokinetics, and preliminary efficacy of YK-029A in treatment-naive patients with advanced NSCLC harboring EGFR exon 20 insertion mutations: a phase 1 trial. J Thorac Oncol. 2024;19(2):314\u201324. https:\/\/doi.org\/10.1016\/j.jtho.2023.09.1449.","journal-title":"J Thorac Oncol"},{"key":"2329_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102724","author":"L Zhang","year":"2024","unstructured":"Zhang L, Fang W, Zhao S, Yu Y, Tang X, Dong X, et al. 137MO Phase II study of becotarug (JMT101) combined with osimertinib in patients (pts) with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion (ex20ins) mutations (BECOME study). ESMO Open. 2024. https:\/\/doi.org\/10.1016\/j.esmoop.2024.102724.","journal-title":"ESMO Open"},{"issue":"10","key":"2329_CR82","doi-asserted-by":"publisher","first-page":"8878","DOI":"10.3390\/ijms24108878","volume":"24","author":"G Pretelli","year":"2023","unstructured":"Pretelli G, Spagnolo CC, Ciappina G, Santarpia M, Pasello G. Overview on therapeutic options in uncommon EGFR mutant non-small cell lung cancer (NSCLC): new lights for an unmet medical need. Int J Mol Sci. 2023;24(10):8878.","journal-title":"Int J Mol Sci"},{"issue":"15","key":"2329_CR83","doi-asserted-by":"publisher","first-page":"e20542","DOI":"10.1200\/JCO.2019.37.15_suppl.e20542","volume":"37","author":"EP Omelchuk","year":"2019","unstructured":"Omelchuk EP, Kit OI, Petrusenko NA, Timoshkina NN, Gvaldin DY, Kalabanova EA, et al. Multiple mutations in the EGFR gene in patients diagnosed with lung cancer. J Clin Oncol. 2019;37(15):e20542. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.e20542.","journal-title":"J Clin Oncol"},{"issue":"75","key":"2329_CR84","doi-asserted-by":"publisher","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","volume":"3","author":"LV Sequist","year":"2011","unstructured":"Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26. https:\/\/doi.org\/10.1126\/scitranslmed.3002003.","journal-title":"Sci Transl Med"},{"issue":"21","key":"2329_CR85","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1002\/cncr.34451","volume":"128","author":"L-L Pang","year":"2022","unstructured":"Pang L-L, Gan J-D, Tan J-R, Huang Y-H, Liao J, Liang W-T, et al. Efficacy and potential resistance mechanisms of afatinib in advanced non\u2013small cell lung cancer patients with EGFR G719X\/L861Q\/S768I. Cancer. 2022;128(21):3804\u201314. https:\/\/doi.org\/10.1002\/cncr.34451.","journal-title":"Cancer"},{"issue":"5","key":"2329_CR86","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.21037\/jtd.2020.03.78","volume":"12","author":"B Gini","year":"2020","unstructured":"Gini B, Thomas N, Blakely CM. Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer. J Thorac Dis. 2020;12(5):2883\u201395.","journal-title":"J Thorac Dis"},{"issue":"1","key":"2329_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02584-z","volume":"9","author":"R Nahar","year":"2018","unstructured":"Nahar R, Zhai W, Zhang T, Takano A, Khng AJ, Lee YY, et al. Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing. Nat Commun. 2018;9(1):216. https:\/\/doi.org\/10.1038\/s41467-017-02584-z.","journal-title":"Nat Commun"},{"issue":"13","key":"2329_CR88","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1158\/1078-0432.Ccr-17-2961","volume":"24","author":"HA Yu","year":"2018","unstructured":"Yu HA, Suzawa K, Jordan E, Zehir A, Ni A, Kim R, et al. Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance. Clin Cancer Res. 2018;24(13):3108\u201318. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-2961.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2329_CR89","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","volume":"15","author":"K Fu","year":"2022","unstructured":"Fu K, Xie F, Wang F, Fu L. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J Hematol Oncol. 2022;15(1):173. https:\/\/doi.org\/10.1186\/s13045-022-01391-4.","journal-title":"J Hematol Oncol"},{"key":"2329_CR90","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.2147\/ott.S106399","volume":"9","author":"J Wang","year":"2016","unstructured":"Wang J, Wang B, Chu H, Yao Y. Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. Onco Targets Ther. 2016;9:3711\u201326. https:\/\/doi.org\/10.2147\/ott.S106399.","journal-title":"Onco Targets Ther"},{"issue":"9","key":"2329_CR91","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1158\/2159-8290.cd-21-0226","volume":"11","author":"CB Meador","year":"2021","unstructured":"Meador CB, Sequist LV, Piotrowska Z. Targeting EGFR Exon 20 insertions in non-small cell lung cancer: recent advances and clinical updates. Cancer Discov. 2021;11(9):2145\u201357. https:\/\/doi.org\/10.1158\/2159-8290.cd-21-0226.","journal-title":"Cancer Discov"},{"key":"2329_CR92","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2147\/pgpm.S242045","volume":"14","author":"L Pacini","year":"2021","unstructured":"Pacini L, Jenks AD, Vyse S, Wilding CP, Arthur A, Huang PH. Tackling drug resistance in EGFR Exon 20 insertion mutant lung cancer. Pharmgenomics Pers Med. 2021;14:301\u201317. https:\/\/doi.org\/10.2147\/pgpm.S242045.","journal-title":"Pharmgenomics Pers Med"},{"key":"2329_CR93","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221146131","volume":"15","author":"JL Low","year":"2023","unstructured":"Low JL, Lim SM, Lee JB, Cho BC, Soo RA. Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations. Ther Adv Med Oncol. 2023;15:17588359221146131. https:\/\/doi.org\/10.1177\/17588359221146131.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"2329_CR94","doi-asserted-by":"publisher","first-page":"4","DOI":"10.21037\/atm.2016.12.09","volume":"5","author":"B Ko","year":"2017","unstructured":"Ko B, He T, Gadgeel S, Halmos B. MET\/HGF pathway activation as a paradigm of resistance to targeted therapies. Ann Transl Med. 2017;5(1):4. https:\/\/doi.org\/10.21037\/atm.2016.12.09.","journal-title":"Ann Transl Med"},{"issue":"6","key":"2329_CR95","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41571-020-0340-z","volume":"17","author":"\u00c1 Quintanal-Villalonga","year":"2020","unstructured":"Quintanal-Villalonga \u00c1, Chan JM, Yu HA, Pe\u2019er D, Sawyers CL, Sen T, et al. Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nat Rev Clin Oncol. 2020;17(6):360\u201371. https:\/\/doi.org\/10.1038\/s41571-020-0340-z.","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"2329_CR96","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1158\/2159-8290.Cd-20-1863","volume":"11","author":"A Quintanal-Villalonga","year":"2021","unstructured":"Quintanal-Villalonga A, Taniguchi H, Zhan YA, Hasan MM, Chavan SS, Meng F, et al. Multiomic analysis of lung tumors defines pathways activated in neuroendocrine transformation. Cancer Discov. 2021;11(12):3028\u201347. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-1863.","journal-title":"Cancer Discov"},{"issue":"1","key":"2329_CR97","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3390\/ijms27010445","volume":"27","author":"LYE Lau","year":"2026","unstructured":"Lau LYE, Skanderup AJ, Tan AC. Lineage plasticity and histologic transformation in EGFR-TKI resistant lung cancer. Int J Mol Sci. 2026;27(1):445.","journal-title":"Int J Mol Sci"},{"key":"2329_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115631","volume":"226","author":"GH Park","year":"2025","unstructured":"Park GH, Park S, Kim H, Jung HA, Sun JM, Ahn JS, et al. Prospective investigation of biomarker and resistance mechanism using longitudinal cell-free NGS in non-small cell lung cancer with EGFR exon 20 insertion treated with Amivantamab. Eur J Cancer. 2025;226:115631. https:\/\/doi.org\/10.1016\/j.ejca.2025.115631.","journal-title":"Eur J Cancer"},{"key":"2329_CR99","doi-asserted-by":"publisher","first-page":"S1245","DOI":"10.1016\/j.annonc.2024.08.2297","volume":"35","author":"B Besse","year":"2024","unstructured":"Besse B, Lee SH, Lu S, Stroyakovskiy D, Yazici O, Rodriguez Cid JR, et al. LBA55 mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: an early analysis from the Phase III MARIPOSA study. Ann Oncol. 2024;35:S1245\u20136. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2297.","journal-title":"Ann Oncol"},{"key":"2329_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102807","volume":"130","author":"M Weller","year":"2024","unstructured":"Weller M, Remon J, Rieken S, Vollmuth P, Ahn M-J, Minniti G, et al. Central nervous system metastases in advanced non-small cell lung cancer: a review of the therapeutic landscape. Cancer Treat Rev. 2024;130:102807. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102807.","journal-title":"Cancer Treat Rev"},{"key":"2329_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1717432","volume":"16","author":"M Sharma","year":"2026","unstructured":"Sharma M, Shah A, Rivera-Caraballo KA, Raval G, Kaur B, Wallace GCt. Brain metastases from non-small cell lung cancer: molecular subtypes and emerging CNS-directed precision therapies. Front Oncol. 2026;16:1717432. https:\/\/doi.org\/10.3389\/fonc.2026.1717432.","journal-title":"Front Oncol"},{"issue":"1","key":"2329_CR102","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s12967-025-06448-9","volume":"23","author":"S Feng","year":"2025","unstructured":"Feng S, Liu H, Yun C, Zhu W, Pan Y. Application of EGFR-TKIs in brain tumors, a breakthrough in future? J Transl Med. 2025;23(1):449. https:\/\/doi.org\/10.1186\/s12967-025-06448-9.","journal-title":"J Transl Med"},{"issue":"3","key":"2329_CR103","doi-asserted-by":"publisher","DOI":"10.1200\/edbk-25-472792","volume":"45","author":"JW Carlisle","year":"2025","unstructured":"Carlisle JW, Wolner Z, Pannu S, Mitchell C, Hsu M, Aijaz A, et al. Bispecific antibodies in non\u2013small cell lung cancer: from targeted innovation to real-world integration. Am Soc Clin Oncol Educ Book. 2025;45(3):e472792. https:\/\/doi.org\/10.1200\/edbk-25-472792.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"8","key":"2329_CR104","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1158\/2159-8290.Cd-20-0116","volume":"10","author":"J Yun","year":"2020","unstructured":"Yun J, Lee S-H, Kim S-Y, Jeong S-Y, Kim J-H, Pyo K-H, et al. Antitumor activity of Amivantamab (JNJ-61186372), an EGFR\u2013MET bispecific antibody, in diverse models of EGFR Exon 20 insertion-driven NSCLC. Cancer Discov. 2020;10(8):1194\u2013209. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-0116.","journal-title":"Cancer Discov"},{"issue":"9","key":"2329_CR105","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40265-024-02073-w","volume":"84","author":"S Dhillon","year":"2024","unstructured":"Dhillon S. Ivonescimab: first approval. Drugs. 2024;84(9):1135\u201342. https:\/\/doi.org\/10.1007\/s40265-024-02073-w.","journal-title":"Drugs"},{"issue":"7","key":"2329_CR106","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jama.2024.10613","volume":"332","author":"Investigators, H.-A.S.","year":"2024","unstructured":"Investigators, H.-A.S. Ivonescimab plus chemotherapy in non\u2013small cell lung cancer with EGFR variant: a randomized clinical trial. JAMA. 2024;332(7):561\u201370. https:\/\/doi.org\/10.1001\/jama.2024.10613.","journal-title":"JAMA"},{"key":"2329_CR107","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.semcancer.2019.12.024","volume":"69","author":"B Ricciuti","year":"2021","unstructured":"Ricciuti B, Lamberti G, Andrini E, Genova C, De Giglio A, Bianconi V, et al. Antibody\u2013drug conjugates for lung cancer in the era of personalized oncology. Semin Cancer Biol. 2021;69:268\u201378. https:\/\/doi.org\/10.1016\/j.semcancer.2019.12.024.","journal-title":"Semin Cancer Biol"},{"issue":"16_suppl","key":"2329_CR108","doi-asserted-by":"publisher","first-page":"9114","DOI":"10.1200\/JCO.2023.41.16_suppl.9114","volume":"41","author":"W Fang","year":"2023","unstructured":"Fang W, Cheng Y, Chen Z, Wang W, Yin Y, Li Y, et al. SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: efficacy and safety data from a Phase 2 study. J Clin Oncol. 2023;41(16_suppl):9114\u20139114. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.9114.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"2329_CR109","doi-asserted-by":"publisher","first-page":"8615","DOI":"10.1200\/JCO.2025.43.16_suppl.8615","volume":"43","author":"L Zhang","year":"2025","unstructured":"Zhang L, Fang W, Cheng Y, Meng X, Yang R, Jiang G, et al. Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated locally advanced or metastatic (LA\/M) non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: preliminary results from a phase 2 study. J Clin Oncol. 2025;43(16_suppl):8615\u20138615. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.8615.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2329_CR110","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa2512071","volume":"394","author":"W Fang","year":"2026","unstructured":"Fang W, Wu L, Meng X, Yao Y, Zuo W, Yao W, et al. Sacituzumab Tirumotecan in EGFR-TKI-resistant, EGFR-mutated advanced NSCLC. N Engl J Med. 2026;394(1):13\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2512071.","journal-title":"N Engl J Med"},{"key":"2329_CR111","unstructured":"Cision, P.N.b. Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) Approved for Marketing in Second Indication by NMPA for EGFRm NSCLC. 2025 [cited 2026; Available from: https:\/\/www.prnewswire.com\/news-releases\/kelun-biotechs-trop2-adc-sacituzumab-tirumotecan-sac-tmt-approved-for-marketing-in-second-indication-by-nmpa-for-egfrm-nsclc-302396917.html."},{"issue":"10","key":"2329_CR112","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1200\/jco-24-01349","volume":"43","author":"J Sands","year":"2025","unstructured":"Sands J, Ahn MJ, Lisberg A, Cho BC, Blumenschein G Jr., Shum E, et al. Datopotamab Deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: results from the Phase II TROPION-Lung05 study. J Clin Oncol. 2025;43(10):1254\u201365. https:\/\/doi.org\/10.1200\/jco-24-01349.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2329_CR113","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1200\/JCO-24-01544","volume":"43","author":"M-J Ahn","year":"2024","unstructured":"Ahn M-J, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, et al. Datopotamab Deruxtecan versus Docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label Phase III TROPION-Lung01 study. J Clin Oncol. 2024;43(3):260\u201372. https:\/\/doi.org\/10.1200\/JCO-24-01544.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2329_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39139-4","volume":"14","author":"S Zhao","year":"2023","unstructured":"Zhao S, Zhuang W, Han B, Song Z, Guo W, Luo F, et al. Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer. Nat Commun. 2023;14(1):3468. https:\/\/doi.org\/10.1038\/s41467-023-39139-4.","journal-title":"Nat Commun"},{"issue":"1","key":"2329_CR115","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","volume":"35","author":"A Passaro","year":"2024","unstructured":"Passaro A, Wang J, Wang Y, Lee SH, Melosky B, Shih JY, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the Phase III MARIPOSA-2 study. Ann Oncol. 2024;35(1):77\u201390. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.117.","journal-title":"Ann Oncol"},{"issue":"5","key":"2329_CR116","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/14796694.2025.2457294","volume":"21","author":"JV Heymach","year":"2025","unstructured":"Heymach JV, Yu HA, Besse B, Cheng Y, Tan DSW, Wei L, et al. REZILIENT3: randomized Phase III study of first-line zipalertinib plus chemotherapy in patients with EGFR exon 20 insertion-mutated NSCLC. Future Oncol. 2025;21(5):549\u201356. https:\/\/doi.org\/10.1080\/14796694.2025.2457294.","journal-title":"Future Oncol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02329-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02329-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02329-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:39:45Z","timestamp":1782196785000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02329-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":116,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2329"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02329-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"14 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Aaron C. Tan\u2014Consulting or Advisor Role: Amgen, AstraZeneca, Bayer, Pfizer; all outside the submitted work. Eunice L.Y. Lau, Noor Rashidha Binte Meera Sahib and Carina Ysha P. Cangco declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No datasets were generated or analyzed during the current study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors were involved in the initial conception of the review. All authors searched and screened all relevant literature. Eunice L.Y. Lau led and consolidated the writing of the manuscript and created Figs.\n                      \n                      and\n                      \n                      . Aaron C. Tan created Fig.\n                      \n                      and Noor Rashidha Binte Meera Sahib created Fig.\n                      \n                      . All authors read and approved the final version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}}]}}